Rainbow Childrens Medicare Limited — Investor Meet, 01-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Rainbow delivered strong Q4 FY26 results: Revenue grew 24% to 459.9 Cr, EBITDA rose 26% to 144.7 Cr (31.5% margin), and PAT surged 38% to 78.2 Cr. For FY26, revenue hit 1,703 Cr (+12%), EBITDA 544 Cr (+11%), and PAT 282 Cr (+15.3%). The company added ~500 beds in FY26, its highest ever.

Management aims for ~20% growth in the current fiscal year, focusing on improving occupancies, clinical excellence, and leveraging technology. Rainbow holds ~600 Cr in cash with no debt. An ambitious pipeline includes over 900 beds under execution in cities like Pune, Coimbatore, Gurugram, and Indore. The IVF segment is expected to grow ~25% annually. The company is confident in its strategic expansion through both organic growth and M&A opportunities in new geographies.